Skip to content

Cefuroxime Sodium

FDA-approved product (injectable, injection), marketed as Cefuroxime And Dextrose In Duplex Container, Cefuroxime Sodium, Cefuroxime Sodium In Plastic Container and 4 more.

Registered studies
50+
Lab records
17
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Cefuroxime Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Eye infection
  • Infection
  • Pneumonia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Second-generation cephalosporins; Antibiotics
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01DC02; WHO ATC S01AA27

Repurposing investigation

Cefuroxime Sodium is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA94.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli77.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae20.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis46.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 6 of 6 lab records
  • E. coli: measured active in 2 of 2 lab records
  • K. pneumoniae: measured active in 1 of 9 lab records
Show the 17 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Cefuroxime Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • APLAUD Trial (Antibiotics vs PLacebo for Acute Uncomplicated Diverticulitis)

    NCT07492134 · start 2026-07-07

    Registered record
    Registry ID
    NCT07492134
    Conditions
    Acute Uncomplicated Diverticulitis
    Interventions
    Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet; Placebo; Metronidazole; Cefuroxime
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-07-07
    Completion
    2028-10-01
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Uncomplicated Diverticulitis
    InterventionAmoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet; Placebo; Metronidazole; Cefuroxime
    PhasePhase 2
    Registry statusRecruiting
  • Prophylactic Antibiotics in Preventing Surgical Site Infection After Hepatobiliary Surgery in High-Resistant Settings

    NCT07620223 · start 2026-05-24

    Registered record
    Registry ID
    NCT07620223
    Conditions
    Hepatobiliary Surgery; Prophylactic Antibiotics
    Interventions
    Piperacillin-tazobactam
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2026-05-24
    Completion
    2029-01-31
    Enrolment
    378

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatobiliary Surgery; Prophylactic Antibiotics
    InterventionPiperacillin-tazobactam
    PhaseNot applicable
    Registry statusRecruiting
  • Efficacy and Safety of Sanyong Jiedu Granules in Treating Lumps-Type Non-Lactational Mastiti

    NCT07512648 · start 2026-03-20

    Registered record
    Registry ID
    NCT07512648
    Conditions
    Plasmacytic Mastitis; Granulomatous Lobular Mastitis
    Interventions
    Sanyong Jiedu Granules; Standard Medication
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-03-20
    Completion
    2028-07-31
    Enrolment
    210

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPlasmacytic Mastitis; Granulomatous Lobular Mastitis
    InterventionSanyong Jiedu Granules; Standard Medication
    PhaseNot applicable
    Registry statusNot yet recruiting
  • Effects of Red and Infrared Photobiomodulation in Rhinoplasty at a Single Centre

    NCT07033039 · start 2026-01-30

    Registered record
    Registry ID
    NCT07033039
    Conditions
    Rhinoplasty; Edema
    Interventions
    Photobiomodulation; Simulation of Photobiomodulation; Standard treatment protocol
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2026-01-30
    Completion
    2030-11-30
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRhinoplasty; Edema
    InterventionPhotobiomodulation; Simulation of Photobiomodulation; Standard treatment protocol
    PhaseNot applicable
    Registry statusRecruiting
  • Pivmecillinam as Oral Step-Down Treatment for Escherichia Coli Febrile Urinary Tract Infection Versus Standard of Care

    NCT07236944 · start 2025-12

    Registered record
    Registry ID
    NCT07236944
    Conditions
    Febrile Urinary Tract Infection
    Interventions
    Pivmecillinam; Standard of Care (Investigator Choice)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-12
    Completion
    2029-03
    Enrolment
    560

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFebrile Urinary Tract Infection
    InterventionPivmecillinam; Standard of Care (Investigator Choice)
    PhasePhase 4
    Registry statusRecruiting
  • Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing

    NCT06406114 · start 2025-05-05

    Registered record
    Registry ID
    NCT06406114
    Conditions
    Drug Allergy; Cephalosporin Allergy; Drug Hypersensitivity; Antibiotic Allergy; Beta Lactam Adverse Reaction; Drug-Induced Anaphylaxis; Cephalosporin Reaction
    Interventions
    Beta-lactam antibiotic (cefazolin, cefuroxime, cefotaxime, ceftazidime, ceftriaxone, cefepime, pre-pen, penicillin G, ampicillin, and histamine) double-blind skin testing; Culprit cephalosporin (cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime) double-blind placebo-controlled drug challenge; Similar cephalosporin (cefepime, ceftriaxone, cefaclor, cephalexin, cefixime, or cefdinir) antibiotic double-blind placebo-controlled drug challenge; Dissimilar cephalosporin (ceftriaxone or cefazolin) antibiotic double-blind placebo-controlled drug challenge; Amoxicillin double-blind placebo-controlled drug challenge
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-05-05
    Completion
    2028-12-31
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug Allergy; Cephalosporin Allergy; Drug Hypersensitivity; Antibiotic Allergy +3 more
    InterventionBeta-lactam antibiotic (cefazolin, cefuroxime, cefotaxime, ceftazidime, ceftriaxone, cefepime, pre-pen, penicillin G, ampicillin, and histamine) double-blind skin testing; Culprit cephalosporin (cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime) double-blind placebo-controlled drug challenge; Similar cephalosporin (cefepime, ceftriaxone, cefaclor, cephalexin, cefixime, or cefdinir) antibiotic double-blind placebo-controlled drug challenge; Dissimilar cephalosporin (ceftriaxone or cefazolin) antibiotic double-blind placebo-controlled drug challenge +1 more
    PhasePhase 2
    Registry statusRecruiting
  • Clinical Trial Testing Whether Targeted Antibiotic Prophylaxis Can Reduce Infections After Cystectomy Compared to Empiric Prophylaxis

    NCT06709196 · start 2025-01-07

    Registered record
    Registry ID
    NCT06709196
    Conditions
    Cystectomy; Bladder Cancer Requiring Cystectomy; Postoperative Infections; Antibiotic Prophylaxis; Ileal Conduit
    Interventions
    Pivmecillinam; Pivmecillinam; Amoxicillin clavulanic acid; Amoxicillin; Cefuroxime; Ciprofloxacin; Linezolid; Nitrofurantoin; Trimethoprim; Sulfamethoxazole trimethoprim; Fluconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-01-07
    Completion
    2027-01
    Enrolment
    248

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystectomy; Bladder Cancer Requiring Cystectomy; Postoperative Infections; Antibiotic Prophylaxis +1 more
    InterventionPivmecillinam; Pivmecillinam; Amoxicillin clavulanic acid; Amoxicillin +7 more
    PhasePhase 4
    Registry statusRecruiting
  • Compound Phellodendron Decoction May Promote Wound Healing After Anal Fistulotomy

    NCT06663527 · start 2024-10-26

    Registered record
    Registry ID
    NCT06663527
    Conditions
    Fistula in Ano
    Interventions
    Fumigating-washing Therapy With CPD; fumigating-washing therapy with a placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2024-10-26
    Completion
    2025-02-01
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFistula in Ano
    InterventionFumigating-washing Therapy With CPD; fumigating-washing therapy with a placebo
    PhaseNot applicable
    Registry statusCompleted
  • Clinical Trial Comparing Oral Versus Intravenous Cefuroxime in Pregnant Women with Pyelonephritis

    NCT06527560 · start 2024-09-09

    Registered record
    Registry ID
    NCT06527560
    Conditions
    Pyelonephritis in Pregnancy
    Interventions
    Cefuroxime; Cefuroxime Axetil
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2024-09-09
    Completion
    2027-12-31
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPyelonephritis in Pregnancy
    InterventionCefuroxime; Cefuroxime Axetil
    PhasePhase 4
    Registry statusRecruiting
  • Colo-Pro_2: Bolus-continuous Infusion Cefuroxime Prophylaxis for the Prevention of Infections After Colorectal Surgery

    NCT05609240 · start 2023-05-10

    Registered record
    Registry ID
    NCT05609240
    Conditions
    Antibiotic Prophylaxis; Colorectal Surgery
    Interventions
    Cefuroxime
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2023-05-10
    Completion
    2025-05-01
    Enrolment
    180

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAntibiotic Prophylaxis; Colorectal Surgery
    InterventionCefuroxime
    PhasePhase 2
    Registry statusUnknown
  • Standard Versus Prolonged Antibiotic Prophylaxis After Pancreatoduodenectomy (SPARROW)

    NCT05784311 · start 2023-03-06

    Registered record
    Registry ID
    NCT05784311
    Conditions
    Pancreatic Cancer
    Interventions
    Cefuroxime; Metronidazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2023-03-06
    Completion
    2026-01
    Enrolment
    344

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPancreatic Cancer
    InterventionCefuroxime; Metronidazole
    PhasePhase 4
    Registry statusRecruiting
  • Medicine-induced Cardiac Hemodialysis on COVID-19

    NCT05711810 · start 2023-01-02

    Registered record
    Registry ID
    NCT05711810
    Conditions
    Severe Acute Respiratory Syndrome-related Coronavirus; Renal Dialysis; Vaccines; Myocarditis Allergic; Infection Viral
    Interventions
    Nifedipine 30 MG; Kangzhu BPCB0A-3A; Low Mobility; Enalapril Maleate 10Mg Tab; Lansoprazole 30Mg Ec Cap; Metoprolol Succinate; Coenzyme Q10; d-alpha tocopherol acetate; Omega-3; Duloxetine Hydrochloride 20 MG Oral Capsule, Delayed Release; Superoxide Dismutase
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2023-01-02
    Completion
    2023-01-12
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSevere Acute Respiratory Syndrome-related Coronavirus; Renal Dialysis; Vaccines; Myocarditis Allergic +1 more
    InterventionNifedipine 30 MG; Kangzhu BPCB0A-3A; Low Mobility; Enalapril Maleate 10Mg Tab +7 more
    PhasePhase 4
    Registry statusCompleted
  • Does Additional Use of Preoperative Azithromycin Decrease Posthysterectomy Infections

    NCT05337566 · start 2022-09-05

    Registered record
    Registry ID
    NCT05337566
    Conditions
    Infection Post Op; Hysterectomy; Antibiotics; Prophylactic
    Interventions
    Azithromycin Pill + Cefuroxime; Placebo + Cefuroxime
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2022-09-05
    Completion
    2030-12
    Enrolment
    2,278

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection Post Op; Hysterectomy; Antibiotics; Prophylactic
    InterventionAzithromycin Pill + Cefuroxime; Placebo + Cefuroxime
    PhaseNot applicable
    Registry statusRecruiting
  • Preoperative Oral Antibiotics With vs Without Mechanical Bowel Preparation to Reduce Surgical Site Infections Following Colonic Resection: an International Randomized Controlled Trial.

    NCT04161599 · start 2022-03-01

    Registered record
    Registry ID
    NCT04161599
    Conditions
    Wounds and Injuries; Surgery--Complications
    Interventions
    Cefuroxime (750mg) I.V; Colonic Surgery; Cefuroxime 750mg oral; Metronidazole 250 MG Oral Tablet [Flagyl]; Metronidazole 1 g Intravenous; Cefuroxime 1,5 g Intravenous; Sodium picosulfate, light magnesium oxide, anhydrous citric acid 10 mg/3.5 g/10.97 g Oral
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2022-03-01
    Completion
    2024-07
    Enrolment
    968

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionWounds and Injuries; Surgery--Complications
    InterventionCefuroxime (750mg) I.V; Colonic Surgery; Cefuroxime 750mg oral; Metronidazole 250 MG Oral Tablet [Flagyl] +3 more
    PhasePhase 4
    Registry statusUnknown
  • Cefuroxime vs Ceftriaxone for SSI Prevention in Neurosurgery

    NCT05398081 · start 2021-12-01

    Registered record
    Registry ID
    NCT05398081
    Conditions
    Surgical Site Infection; Antibiotics Prophylaxis
    Interventions
    Cefuroxime (Zinnat®); Ceftriaxone (Rocephin®)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-12-01
    Completion
    2022-03-05
    Enrolment
    96

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSurgical Site Infection; Antibiotics Prophylaxis
    InterventionCefuroxime (Zinnat®); Ceftriaxone (Rocephin®)
    PhasePhase 2
    Registry statusCompleted